Low-dose 0.01% atropine eye drops safely slowed myopia progression in children with myopia and intermittent exotropia, with some compromise on accommodative amplitude.
Exotropia often coexists with myopia, but previous clinical trials on atropine for myopia have excluded children with strabismus. Investigating the use of atropine for myopia control in this population was the objective of the AMIXT randomized clinical trial at Nanjing Medical University in China.
Three hundred children aged 6 to 12 years with basic-type intermittent exotropia and myopia of –0.5 D to –6 D were